Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: C. difficile vaccine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

NCT02052726
View directory record Official record
Conditions
Clostridium Difficile
Interventions
C. difficile vaccine with adjuvant, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

NCT01230957
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant), Clostridium difficile toxoids A and B (high-dose without adjuvant), Placebo: 0.9% normal saline
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
40 Years to 75 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
30
States / cities
Redding, California • Bristol, Connecticut • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

NCT02561195
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile Vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
17
States / cities
DeLand, Florida • Hollywood, Florida • South Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

NCT02316470
View directory record Official record
Conditions
Clostridium Difficile
Interventions
VLA84, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
Huntsville, Alabama • Chula Vista, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

NCT00214461
View directory record Official record
Conditions
Clostridium Infections
Interventions
Vaccine diluent buffer (Placebo), C. difficile toxoid vaccine (2 µg), C. difficile toxoid vaccine (10 µg), C. difficile toxoid vaccine (50 µg)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Orlando, Florida • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

NCT02117570
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
12
States / cities
DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 15, 2026, 10:00 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

NCT01887912
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
9,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
142
States / cities
Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

NCT01706367
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
C. difficile vaccine, C. difficile vaccine +adjuvant
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 15, 2026, 10:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
23
States / cities
Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 15, 2026, 10:00 PM EDT